MedTrace Logo

EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy -

NCT04687124 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-12-29

No results posted yet for this study

Summary

Malnutrition occurs frequently in patients with cancer during and after radiotherapy to the gastrointestinal (GI) area and can lead to negative outcomes. N-3 fatty acids from fish, especially eicosapentaenoic acid (EPA) may possess anticachectic properties. The aim of this study is to investigate the effect of two nutritional interventions; dietary counselling and an oral nutritional supplement (ONS) containing 2.2 g of the n-3 fatty acid EPA (Forticare®) or standard care, including dietary counselling and protein supplementation when needed.

Conditions

  • Abdominal Cancer
  • Radiotherapy; Complications
  • Weight Loss
  • Energy Supply
  • Protein Deficiency

Interventions

DIETARY_SUPPLEMENT

Fish oil

Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)

OTHER

standard care

No specified intervention

Sponsors & Collaborators

  • Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen

    collaborator UNKNOWN

  • Jens Rikardt Andersen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2021-01-31
Completion
2021-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04687124 on ClinicalTrials.gov